NXTC NextCure Inc.

27.14
+0.96  (+4%)
Previous Close 26.18
Open 26.35
Price To Book 3.45
Market Cap 616,478,722
Shares 22,714,765
Volume 53,625
Short Ratio
Av. Daily Volume 89,368
Stock charts supplied by TradingView

NewsSee all news

  1. NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

    BELTSVILLE, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  2. NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

    BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data due at SITC November 9, 2019; 4:15 pm ET. Phase 2 part to be completed 4Q 2020.
NC318
Solid tumors

Latest News

  1. NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

    BELTSVILLE, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  2. NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

    BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer